Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows revision v3.5.4 instead of v3.5.3, representing a newer version of the record and a metadata refresh rather than a substantive change to the study details.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s UI/build “Revision” marker was updated from v3.5.2 to v3.5.3. This reflects a platform version change rather than an update to the trial details.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.5.2 is now displayed, replacing Revision: v3.5.0. This appears to be an internal version update with no changes to the study content.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded revision note v3.5.0 and removed revision note v3.4.3.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision updated to v3.4.3; the prior revision v3.4.2 is superseded. This appears to be a metadata update with no changes to the study details.SummaryDifference0.1%

- Check106 days agoChange DetectedAddition of Revision: v3.4.2 and deletion of notices about government funding lapse and prior Revision: v3.4.1. These updates are administrative in nature and do not modify study data or core page content.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.